INT36978

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.73
First Reported 1987
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 9
Total Number 9
Disease Relevance 7.43
Pain Relevance 0.82

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
vasculature 1
smooth muscle 1
fibroblast 1
connective tissue 1
chemoreceptor cells 1
Pah (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Serotonin 27 98.72 Very High Very High Very High
fibrosis 10 96.60 Very High Very High Very High
anesthesia 2 88.88 High High
Calcium channel 34 77.48 Quite High
halothane 1 73.28 Quite High
rheumatoid arthritis 2 69.92 Quite High
antagonist 98 68.84 Quite High
imagery 4 65.68 Quite High
Clonidine 4 58.48 Quite High
tolerance 14 42.44 Quite Low
Disease Link Frequency Relevance Heat
Pulmonary Hypertension 898 100.00 Very High Very High Very High
Disease 83 100.00 Very High Very High Very High
Hypertrophy 42 99.68 Very High Very High Very High
Airway Obstruction 8 99.60 Very High Very High Very High
Hypertension 12 99.46 Very High Very High Very High
Cystic Fibrosis 4 96.88 Very High Very High Very High
Asthma 4 96.20 Very High Very High Very High
Bronchopulmonary Dysplasia 4 95.80 Very High Very High Very High
Increased Venous Pressure Under Development 90 93.52 High High
Systemic Sclerosis 36 92.88 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
High doses of furosemide (120 mg/kg as intravenous bolus) reversibly decreased the CPAH/CTEA ratio, suggesting that furosemide may compete for PAH secretion in the proximal tubule.
Localization (secretion) of PAH in tubule
1) Confidence 0.73 Published 1987 Journal Ren Physiol Section Abstract Doc Link 3447247 Disease Relevance 0.07 Pain Relevance 0.09
Hence, the aims of the present study were to determine the effects of blockade of purinoceptors with suramin, or suppression of PAH activity with iron chelator CPX, and with the oxoglutarate analogue dimethyloxalylglycine (DMOG), on the endogenous NO release produced in some intraglomic structure, probably chemoreceptor cells and efferent fibers.


Neg (NO) Localization (release) of PAH in chemoreceptor cells
2) Confidence 0.65 Published 2007 Journal The Open Biochemistry Journal Section Body Doc Link PMC2570544 Disease Relevance 0.43 Pain Relevance 0.11
These effects on pulmonary vasculature appear to occur independently of the cause of PAH, suggesting a role in the management of IPAH.62
Localization (cause) of PAH in vasculature associated with pulmonary hypertension
3) Confidence 0.59 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2697585 Disease Relevance 0.75 Pain Relevance 0.22
Patients with PAH have increased levels of circulating endothelin-1.22,23 As well as causing vasoconstriction, endothelin-1 leads to smooth muscle and fibroblast proliferation via endothelin A (ETA), and/or endothelin B (ETB) receptors.24 Serotonin levels are also raised in PAH, which stimulates mitogenesis of vascular cells, and increased expression of the serotonin transporter is found in hypertensive arteries.25 Patients with severe PAH have a relative deficiency of vasodilator pathways; they produce less endogenous prostacyclin, have reduced nitrogen oxide synthase (NOS) expression, and reduced vasoactive intestinal peptide (VIP) in the lungs.26,27

Prevention of pediatric pulmonary hypertension

Localization (severe) of PAH in smooth muscle associated with pulmonary hypertension, hypertension, increased venous pressure under development and serotonin
4) Confidence 0.52 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2697585 Disease Relevance 0.97 Pain Relevance 0.13
For example, patients whose PAH is caused by upper airway obstruction might undergo adenotonsillectomy, and those with cystic fibrosis, asthma or bronchopulmonary dysplasia should be managed with the relevant therapeutics.
Localization (caused) of PAH in upper associated with asthma, fibrosis, pulmonary hypertension, cystic fibrosis, airway obstruction and bronchopulmonary dysplasia
5) Confidence 0.52 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2697585 Disease Relevance 1.48 Pain Relevance 0.11
To study whether in vivo modulation of Cav-1 expression could affect the development of PAH and RV hypertrophy, rats were injected with MCT, followed by a daily injection of (1) saline, (2) a peptide corresponding to the homeodomain of the Drosophila transcription factor antennapedia (AP; 2.5?
Localization (development) of PAH associated with hypertrophy and pulmonary hypertension
6) Confidence 0.49 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2843902 Disease Relevance 0.85 Pain Relevance 0
Bosentan in connective tissue disease associated PAH
Localization (disease) of PAH in connective tissue associated with pulmonary hypertension and disease
7) Confidence 0.40 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350123 Disease Relevance 1.39 Pain Relevance 0.03
The authors reported on 169 patients with idiopathic PAH who received bosentan as first line therapy for their disease.
Localization (reported) of PAH associated with pulmonary hypertension and disease
8) Confidence 0.40 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350123 Disease Relevance 0.51 Pain Relevance 0
Patients with PAH have increased levels of circulating endothelin-1.22,23 As well as causing vasoconstriction, endothelin-1 leads to smooth muscle and fibroblast proliferation via endothelin A (ETA), and/or endothelin B (ETB) receptors.24 Serotonin levels are also raised in PAH, which stimulates mitogenesis of vascular cells, and increased expression of the serotonin transporter is found in hypertensive arteries.25 Patients with severe PAH have a relative deficiency of vasodilator pathways; they produce less endogenous prostacyclin, have reduced nitrogen oxide synthase (NOS) expression, and reduced vasoactive intestinal peptide (VIP) in the lungs.26,27

Prevention of pediatric pulmonary hypertension

Localization (severe) of PAH in fibroblast associated with pulmonary hypertension, hypertension, increased venous pressure under development and serotonin
9) Confidence 0.18 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2697585 Disease Relevance 0.97 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox